Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Sandler

Showing results (41-50 of 90) with videos related to

Pageof 9
Sort By:
Clinical Lung Cancer|May 18, 2012
Identifying barriers associated with enrollment of patients with lung cancer into clinical trialsLeora Horn, Vicki L Keedy, Norma Campbell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2008
Development of clinical trials in a cooperative group setting: the eastern cooperative oncology groupDavid M Dilts, Alan Sandler, Steven Cheng, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 21, 2015
Incidence trends of lung cancer by immigration status among Chinese AmericansScarlett Lin Gomez, Juan Yang, Shih-Wen Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2005
Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxelIldiko Csiki, Jason D Morrow, Alan Sandler, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 7, 2014
A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancerJeffrey Crawford, Paul Swanson, Paul Schwarzenberger, et al.
Journal of Global Oncology|July 19, 2017
Lung Cancer Survival Among Chinese Americans, 2000 to 2010Scarlett Lin Gomez, Juan Yang, Shih-Wen Lin, et al.
Lung Cancer (Amsterdam, Netherlands)|July 18, 2003
Ongoing and future trials of biologic therapies in lung cancerPaul A Bunn, Frances A Shepherd, Alan Sandler, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2012
Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysisAriel Lopez-Chavez, Todd Young, Sophie Fages, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2009
Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancerGeorge R Blumenschein, Karen Reckamp, G Joe Stephenson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2007
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancerRoy S Herbst, Vincent J O'Neill, Louis Fehrenbacher, et al.
Pageof 9

Showing results (41-50 of 90) with videos related to

Sort By:
Pageof 9
Clinical Lung Cancer|May 18, 2012
Identifying barriers associated with enrollment of patients with lung cancer into clinical trialsLeora Horn, Vicki L Keedy, Norma Campbell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2008
Development of clinical trials in a cooperative group setting: the eastern cooperative oncology groupDavid M Dilts, Alan Sandler, Steven Cheng, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 21, 2015
Incidence trends of lung cancer by immigration status among Chinese AmericansScarlett Lin Gomez, Juan Yang, Shih-Wen Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2005
Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxelIldiko Csiki, Jason D Morrow, Alan Sandler, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 7, 2014
A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancerJeffrey Crawford, Paul Swanson, Paul Schwarzenberger, et al.
Journal of Global Oncology|July 19, 2017
Lung Cancer Survival Among Chinese Americans, 2000 to 2010Scarlett Lin Gomez, Juan Yang, Shih-Wen Lin, et al.
Lung Cancer (Amsterdam, Netherlands)|July 18, 2003
Ongoing and future trials of biologic therapies in lung cancerPaul A Bunn, Frances A Shepherd, Alan Sandler, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2012
Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysisAriel Lopez-Chavez, Todd Young, Sophie Fages, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2009
Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancerGeorge R Blumenschein, Karen Reckamp, G Joe Stephenson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2007
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancerRoy S Herbst, Vincent J O'Neill, Louis Fehrenbacher, et al.
Pageof 9